Trade Show

Reprieve Cardiovascular Builds Clinical Momentum with Positive Results from FASTR Pilot Trial and FDA Investigational Device Exemption Approval for Pivotal Trial

ITN10 hours ago

MILFORD, Mass.–(BUSINESS WIRE)–Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) treatment, today announced topline results from its FASTR randomized pilot study, evaluating the Reprieve System for patients with ADHF compared to optimal diuretic therapy (ODT). The trial met both primary efficacy and safety endpoints. The results were presented by James Udelson, M.D., Principal Investigator of the FASTR trial and Chief of C

ITN

Today we live in a T-shaped world. While broad knowledge across the ecosystems is critical, deep insights and expertise of Subject Matter Experts help organizations leapfrog. At IndiaTechnologyNews, we cover much more than news, views and analysis, and we feature SMEs to help translate their knowledge to wider audiences. Reach me at editor@indiatechnologynews.in